Project Grant R01HL183091
Award Date 8/20/26
Completion Date 5/31/30
Dollars Obligated $726K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $778,582 on August 15, 2026, to identify genetic variants that perturb gene regulatory responses to athero-protective and athero-prone hemodynamic waveforms in human endothelial cells. The award funds research under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates how natural genetic variation governs endothelial cell responses to hemodynamic shear stress from blood flow, with...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Arizona $650,419 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how myosin and cardiac thin filament mutations cause allosteric dysfunction in hypertrophic cardiomyopathy. The research extends a program studying sarcomere function in health and disease. The project develops coupled time-resolved FRET computation-based methods to characterize...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $562,733 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop small molecule therapeutics for heart failure through reduction in tristetraprolin activity and improvement of cardiac metabolism. The project runs through May 31, 2027, with work performed in Tucson, Arizona. The research targets tristetraprolin, a zinc finger protein that regulates fatty acid uptake and oxidation...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $748,677 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle delivery systems targeting lung endothelial cell repair in pediatric acute respiratory distress syndrome (ARDS). The research addresses the lack of innovative molecular approaches to pediatric ARDS management by engineering lung endothelial cell-specific nanoparticle carriers capable of delivering...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $108,950 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoplatforms for co-delivery of drugs and genes to protect lung endothelium from neonatal and pediatric lung injury. The recipient will optimize nanoparticle formulations for stability, safety, and endothelial targeting in neonatal lungs, characterizing physicochemical properties that influence targeting...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Arizona $558,127 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardiac SK channel remodeling in heart disease and arrhythmias. The research combines experimental and computational studies to address gaps in understanding small-conductance Ca²⁺-activated K⁺ channels (SK channels) in diseased hearts. The work focuses on two primary challenges: the...
- Grant Award Summary The University of Arizona received a $576,786 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion targeted for August 31, 2028. This research initiative investigates protein translation mechanisms underlying oxidative stress response in heart failure, specifically examining the role of YTHD2 (a YTH domain-containing N6-methyladenosine binding...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Arizona $743,545 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods for drug discovery targeting atrial fibrillation. The research focuses on identifying selective inhibitors of small conductance calcium-activated potassium (SK) channels as a therapeutic approach to atrial fibrillation. The project builds on the investigative...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $577,065 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the roles of endoplasmic reticulum stress in calcium-dependent cardiac arrhythmias. The research addresses how endoplasmic reticulum stress response contributes to acquired cardiovascular diseases with high arrhythmic risk, particularly those involving hyperactivity of the ryanodine receptor (RYR2), the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $375,381 on September 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a small-molecule drug discovery platform targeting MYBPC1 mutations that cause distal arthrogryposis. The project addresses the absence of available therapeutics for distal arthrogryposis, a congenital muscle disorder affecting approximately 1 in 3,000 live births...